SEC Filing Summary for Eric Pauwels

Eric Pauwels, Chief Business Officer of PTC Therapeutics, Inc., reported several transactions on December 19, 2025. These transactions involved the acquisition and disposal of Common Stock and Stock Options. Notably, Pauwels acquired 138 shares of Common Stock at $66.49 per share and 565 shares at $18.01 per share. He also acquired 19805 shares at $66.49 per share. Concurrently, he disposed of various amounts of Common Stock at weighted average prices ranging from $75.20 to $78.49, as detailed in the footnotes. Additionally, Pauwels exercised and disposed of stock options. These transactions were executed under a Rule 10b5-1 plan. Following these transactions, his reported post-transaction share ownership varies across different entries, with a significant increase in total shares held in some cases.